{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:19:28Z","timestamp":1793233168093,"version":"4.5.0"},"reference-count":86,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T00:00:00Z","timestamp":1506038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>\n                    Huntington's disease (\n                    <jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>\n                    ) is a fully penetrant neurodegenerative disease caused by a dominantly inherited\n                    <jats:styled-content style=\"fixed-case\">CAG<\/jats:styled-content>\n                    trinucleotide repeat expansion in the huntingtin gene on chromosome 4. In Western populations\n                    <jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>\n                    has a prevalence of 10.6\u201313.7 individuals per 100 000. It is characterized by cognitive, motor and psychiatric disturbance. At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses. There are currently no disease modifying treatments; therefore supportive and symptomatic management is the mainstay of treatment. In recent years there have been significant advances in understanding both the cellular pathology and the macroscopic structural brain changes that occur as the disease progresses. In the last decade there has been a large growth in potential therapeutic targets and clinical trials. Perhaps the most promising of these are the emerging therapies aimed at lowering levels of mutant huntingtin. Antisense oligonucleotide therapy is one such approach with clinical trials currently under way. This may bring us one step closer to treating and potentially preventing this devastating condition.\n                  <\/jats:p>","DOI":"10.1111\/ene.13413","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T10:52:42Z","timestamp":1502967162000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1059,"title":["Huntington's disease: a clinical review"],"prefix":"10.1111","volume":"25","author":[{"given":"P.","family":"McColgan","sequence":"first","affiliation":[{"name":"Huntington's Disease Centre Department of Neurodegenerative Disease UCL Institute of Neurology London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Tabrizi","sequence":"additional","affiliation":[{"name":"Huntington's Disease Centre Department of Neurodegenerative Disease UCL Institute of Neurology London"},{"name":"National Hospital for Neurology and Neurosurgery Queen Square London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww165"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30280-6"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0494-409"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70245-3"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","article-title":"Corticostriatal synaptic adaptations in Huntington's disease","volume":"33","author":"Plotkin JL","year":"2015","journal-title":"Curr Opin Neurobiol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008287"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.10.038"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199805000-00001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198511000-00003"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70276-3"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_2_11_16_1","first-page":"16","article-title":"Phenotypic characterization of individuals with 30\u221240 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u221239 repeats","volume":"59","author":"Rubinsztein DC","year":"1996","journal-title":"Am J Hum Genet"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26001"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24024"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington's disease","volume":"162","author":"Genetic Modifiers of Huntington's Disease Cohort","year":"2015","journal-title":"Cell"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30161-8"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1184"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029522"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.991"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70238-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70170-X"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.002"},{"key":"e_1_2_11_27_1","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey ER","year":"2013","journal-title":"JAMA Neurol"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000204230.16619.d9"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20332"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26021"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25864"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301940"},{"key":"e_1_2_11_34_1","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd D","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307343"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1399-0004.2011.01778.x","article-title":"Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1\/2 hereditary breast\/ovarian cancer","volume":"81","author":"Meer LB","year":"2012","journal-title":"Clin Genet"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21915"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000061"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3282f12074"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2013-000790"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2012.01900.x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.8.1369"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201291"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0739-9"},{"key":"e_1_2_11_45_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study G","year":"2006","journal-title":"Neurology"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4"},{"key":"e_1_2_11_47_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Huntington\u2010Study Group","year":"2016","journal-title":"JAMA"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12483"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30144-4"},{"key":"e_1_2_11_50_1","first-page":"CD009444","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li Y","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25750"},{"key":"e_1_2_11_52_1","unstructured":"McColganP CraufurdD TabriziS.http:\/\/bestpractice.bmj.com\/best-practice\/monograph\/513.html(accessed 10 July 2017)."},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70263-0"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30124-2"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3044-08.2008"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504921102"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/pr0700753"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64565"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-160196"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80743"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13719"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163479"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.21205"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-150173"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv259"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv145"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv214"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170245"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"e_1_2_11_71_1","unstructured":"Teva.Teva announces results from exploratory 52\u2010week phase 2 PRIDE\u2010HD study of pridopidine in Huntington disease 2016."},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70262-5"},{"key":"e_1_2_11_73_1","unstructured":"Raptor Pharmaceuticals.Raptor Pharmaceuticals announces phase 2\/3 clinical trial results with cysteamine (RP103) in Huntington's disease.Novato CA:Raptor Pharmaceuticals 2014."},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn273"},{"key":"e_1_2_11_75_1","doi-asserted-by":"crossref","first-page":"S47\u2010004","DOI":"10.1212\/WNL.82.10_supplement.S47.004","article-title":"Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double\u2010blind, placebo\u2010controlled phase II trial (S47.004)","volume":"82","author":"Reilmann R","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.10.064"},{"key":"e_1_2_11_77_1","unstructured":"Huntington Study Group.Brief report: Pfizer Amaryllis trial ends: negative results lead to termination of extension study.2016."},{"key":"e_1_2_11_78_1","unstructured":"ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02519036(accessed 21 May 2017)."},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2321"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1250127"},{"key":"e_1_2_11_82_1","unstructured":"EmD.Screening approaches to identify small\u2010molecule modulators of huntingtin protein levels. CHDI Foundation Annual Therapeutics Conference. Malta 2017."},{"key":"e_1_2_11_83_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","article-title":"Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long\u2010term mutant huntingtin repression in mice","volume":"11","author":"Agustin\u2010Pavon C","year":"2016","journal-title":"Mol Neurodegener"},{"key":"e_1_2_11_84_1","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele\u2010specific CRISPR\/Cas9","volume":"25","author":"Shin JW","year":"2016","journal-title":"Hum Mol Genet"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92087"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4293"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.11184"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.13413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.13413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T05:59:51Z","timestamp":1719381591000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.13413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,22]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/ene.13413"],"URL":"https:\/\/doi.org\/10.1111\/ene.13413","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,22]]},"assertion":[{"value":"2017-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}